Cancer gene therapy using a pro-apoptotic gene, caspase-3

Gene Ther. 1999 Dec;6(12):1952-9. doi: 10.1038/sj.gt.3301041.

Abstract

Caspase-3 is a member of the cysteine protease family, which plays a crucial role in apoptosis. We applied the human caspase-3 gene as a novel form of anticancer gene therapy. Overexpression of human caspase-3 alone could not induce apoptosis of tumor cell lines, but apoptosis was markedly enhanced by the addition of etoposide. In an AH130 liver tumor model, transduction of human caspase- 3, but not the empty vector, induced extensive apoptosis and reduced tumor volume when combined with etoposide administration. However, this effect was not observed with a Bcl-2 overexpressing tumor. In conclusion, caspase-3 gene transduction accompanied by an additional death stimulus may be a useful method of anticancer gene therapy, except for Bcl-2 overexpressing tumors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviridae / genetics
  • Animals
  • Apoptosis / genetics*
  • Caspase 3
  • Caspases / genetics*
  • Combined Modality Therapy
  • Etoposide / therapeutic use
  • Gene Transfer Techniques*
  • Genetic Therapy / methods*
  • Genetic Vectors
  • Humans
  • In Situ Nick-End Labeling
  • Liver Neoplasms, Experimental / drug therapy
  • Liver Neoplasms, Experimental / therapy*
  • Neoplasm Transplantation
  • Nucleic Acid Synthesis Inhibitors / therapeutic use
  • Rats
  • Tumor Cells, Cultured / drug effects

Substances

  • Nucleic Acid Synthesis Inhibitors
  • Etoposide
  • CASP3 protein, human
  • Casp3 protein, rat
  • Caspase 3
  • Caspases